Recent research is changing how we manage low risk prostate cancer. In this BackTable Urology Podcast episode, Dr. Dan Lin, a urologist at the University of Washington, walks through contemporary diagnosis, surveillance, and management of Grade Group 2 prostate cancer with host Dr. Aditya Bagrodia.

---

This podcast is supported by:

Veracyte

https://www.veracyte.com/decipher

---

SYNPOSIS

The doctors delve into real-world implementation of active surveillance, alongside the use of advanced diagnostics, biopsy methods, and personalized care plans. The conversation highlights the Canary Prostate Active Surveillance Study (PASS) and the prognostic role of biomarkers and genomic testing. Dr. Lin and Dr. Bagrodia also discuss how lifestyle factors such as diet impact cancer progression and how patients can be empowered to manage their disease. Strategies for transitioning patients off surveillance are highlighted. Finally, the two experts discuss insights from recent clinical trials like PIVOT, PROTECT, and SPCG and how they’re impacting prostate cancer management.

---

TIMESTAMPS

00:00 - Introduction

02:54 - Active Surveillance and Canary PASS Data

12:02 - Biopsy Considerations

19:44 - Active Surveillance Protocols

26:58 - Patient Concerns and Risk Reduction

30:52 - Transitioning Off Surveillance

33:39 - Grade Group 2: Treatment vs. Monitoring

46:24 - Surgical Considerations and Node Dissection

49:25 - Future Directions

---

RESOURCES

Veracyte

https://www.veracyte.com/